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AbstrAct
Objective inflammatory back pain (iBP), the key symptom 
of axial spondyloarthritis (axSpa), including ankylosing 
spondylitis, has been proposed as a screening test for 
patients presenting with chronic back pain in primary care. 
the diagnostic accuracy of iBP in the rheumatology setting 
is unknown.
Methods Six rheumatology centres, representing 
secondary and tertiary rheumatology care, included 
routinely referred patients with consecutive chronic back 
pain with suspicion of axSpa. iBP (diagnostic test) was 
assessed in each centre by an independent (blinded) 
rheumatologist; a second (unblinded) rheumatologist 
made the diagnosis (axSpa or no-axSpa), which served as 
reference standard.
Results Of 461 routinely referred patients, 403 
received a final diagnosis. iBP was present in 67.3%, 
and 44.6% (180/403) were diagnosed as axSpa. the 
sensitivity of iBP according to various definitions (global 
judgement, calin, Berlin, assessment of Spondyloarthritis 
international Society criteria for iBP) was 74.4%–81.1 
% and comparable to published figures, whereas the 
specificity was unexpectedly low (25.1%–43.9%). the 
resulting positive likelihood ratios (lr+) were 1.1–1.4 and 
without major differences between sets of iBP criteria. the 
presence of iBP according to various definitions increased 
the probability of axSpa by 2.5%–8.4% only (from 44.6% 
to 47.1%–53.0%).
Conclusions the diagnostic utility of iBP in the 
rheumatology setting was smaller than expected. However, 
this was counterbalanced by a high prevalence of iBP 
among referred patients, demonstrating the effective 
usage of iBP in primary care as selection parameter for 
referral to rheumatology. notably, this study illustrates 
potential shifts in specificity and lr+ of diagnostic tests if 
these tests are used to select patients for referral.
InTROduCTIOn
Inflammatory back pain (IBP) is the key 
clinical symptom of axial spondyloarthritis 
(axSpA), including non-radiographic axSpA 
(nr-axSpA) and ankylosing spondylitis (AS, 
r-axSpA), and is often present at disease 
onset. IBP describes a spectrum of symptoms 
including (1) insidious onset of back pain, 
(2) morning stiffness in the lower back, (3) 
improvement of back pain with exercise, (4) 
no improvement with rest, (5) awakening at 
night or early morning because of back pain 
and (6) alternating buttock pain. Defined 
sets of IBP criteria are the Calin criteria,1 
Berlin criteria2 and the Assessment of Spon-
dyloArthritis international Society (ASAS) 
IBP experts criteria3; the latter was applied 
in the ASAS classification criteria for axSpA 
study.4 5 The published sensitivities (70.1%–
95%) and specificities (72.5%–81.3%%) for 
various sets of IBP criteria reveal calculated 
Key messages 
What is already known about this subject?
 ► inflammatory back pain (iBP), the key symptom in 
axial Spa, is used for diagnostic purposes.
 ► Despite, its diagnostic accuracy in the rheuma-
tology setting according to high level standards 
(e.g. StarD, Standards for reporting of Diagnostic 
accuracy) is unknown.
What does this study add?
 ► in the rheumatology setting iBP was a common find-
ing among referred patients suggesting the effective 
use of iBP as selection parameter for referral in pri-
mary care.
 ► as a result, the specificity of iBP was lower and the 
diagnostic gain of iBP was smaller than expected.
 ► in the rheumatology setting no striking differences 
among defined iBP criteria (calin, Berlin, aSaS) were 
found, yet the calin criteria were least specific.
How might this impact on clinical practice?
 ► the study shows global judgement on the presence 
or absence of iBP as done in routine rheumatolog-
ical care is influenced by knowledge of other Spa 
features.
 ► rheumatologists should realize that diagnostic test 
characteristics such as specificity and likelihood ra-
tios vary if the diagnostic test is used as selection 
parameter in primary care.
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positive likelihood ratios (LR+), a measure of diagnostic 
utility, of 2.9–3.9. Accordingly, a LR+ of 3–4 for IBP has 
been proposed as best estimate for diagnostic purposes 
in daily practice.6 Assuming a background prevalence 
of 5% of axSpA among patients with chronic back pain 
in primary care, it has further been estimated that the 
presence of IBP increases the likelihood of axSpA by 
9%–11% (from 5% to 14%–16%).6 IBP has also been 
proposed7 and has been proven effective as a parameter 
for selecting patients with chronic back pain in primary 
care for referral to rheumatology.7–13 No diagnostic 




The Diagnostic Accuracy of Inflammatory Back pain 
study (DIVERS) was designed according to recommen-
dations in the field of diagnostic studies including the 
Standards for Reporting of Diagnostic Accuracy recom-
mendations.14 15 DIVERS was conducted in six rheuma-
tology centres across Germany: four general rheuma-
tology practices (secondary care) distributed across the 
country, one large hospital for rheumatic diseases and 
one university hospital (tertiary care).
Patients
Eligible patients were routinely referred to rheuma-
tology, had to have chronic back pain of ≥3 months and 
age at onset of ≤45 years and no clear diagnosis. Patients 
with a known diagnosis of axSpA were excluded. To 
avoid selection bias, participating centres were strongly 
encouraged to include consecutively all newly referred 
patients with chronic back pain with suspicion of axSpA. 
No specific referral strategies were set up for this study.
study procedures
In each centre, two rheumatologists were involved: 
R-care and R-blind. R-care took routine care of the 
patient, ordered diagnostic tests as needed and made 
the final diagnosis of axSpA or no-axSpA. In contrast, 
R-blind took the clinical history regarding IBP features 
only, but was blinded to all other disease features 
otherwise. Both R-care and R-blind documented their 
findings independently of each on a prespecified case 
report form. The clinical diagnosis (axSpA or non-SpA) 
made by R-care served as reference standard. Since the 
study was conducted in routine rheumatology care, the 
sequence of consultation by either R-care or R-blind 
was left to the discretion of the participating centres 
and was driven primarily by feasibility aspects (R-care 
first 76%, R-blind first 24%).
In addition, patients were asked to complete a short 
self-reported questionnaire on IBP features in the rheu-
matologist’s waiting room prior to the consultation, 
with answering modalities of ‘yes’ or 'no’ to each IBP 
question.
The time period between first presentation to the 
rheumatology centre including the assessment of IBP 
by R-blind and final diagnosis (axSpA or no-axSpA) was 
in the range of 2–8 weeks. The first patient was included 
in March 2009 and the last patient in June 2010.
study end points and data analysis
The diagnostic test of interest (presence/absence of 
IBP) was assessed by R-blind according to four defini-
tions: (1) IBP by global judgement by the rheumatolo-
gist (ie, judgement on IBP independent of formal IBP 
criteria; yes/no), (2) Calin criteria, (3) Berlin criteria 
and (4) ASAS criteria for IBP. The global judgement 
(yes/no) on IBP was further categorised into ‘uncer-
tain’, ‘moderately confident’, ‘confident’ and ‘very 
confident’. Sensitivity, specificity, positive and negative 
LRs (LR+ and LR−), positive and negative predictive 
values (PPV and NPV) with corresponding 95% CI of 
IBP and the net increase (%) in disease probability of 
axSpA were calculated. The agreement on the pres-
ence of IBP between R-blind and R-care was assessed by 
percentage agreement and Cohen’s kappa; the latter 
interpreted according to the method of Landis and 
Koch.16
ResulTs
Of 476 eligible patients, 13 patients did not fulfil the 
inclusion criteria and were excluded. R-blind decided 
on the presence/absence of IBP in 461/463 patients. 
IBP by global judgement (R-blind) was present in 
306/461 patients (66.4%). The level of confidence on 
IBP by R-blind in these 461 patients was as following: 
‘very confident’ in 17.1% of patients, ‘confident’ in 
62.5%, ‘moderately confident’ in 18.9% and ‘uncer-
tain’ in 1.5%. The final clinical diagnosis by R-care 
(reference standard) was missing in four and consid-
ered uncertain in 54 patients. Thus, 403 patients with 
an assessment of IBP by R-blind (67.3% had IBP) 
and a definite diagnosis by R-care (180 with definite 
axSpA—88 with AS, 92 with nr-axSpA—and 223 with 
no-axSpA) were included in the final analysis (patient 
flow chart shown in figure 1). The clinical characteris-
tics of the patients are presented in table 1. The prev-
alence of IBP was generally higher in patients with 
axSpA (with no difference between AS and nr-axSpA) 
as compared with patients without axSpA (table 2).
The formal agreement on the global judgement 
on the presence of IBP between R-blind and R-care 
was moderate (kappa 0.45; 95% CI 0.36 to 0.54) with 
percentage agreement 74.9%. Similar rates of agree-
ment between R-blind and R-care were obtained for the 
various defined IBP criteria: kappa 0.43 (95% CI 0.32 
to 0.53; percentage agreement 80.2%) for the Calin 
criteria; kappa 0.52 (95% CI 0.43 to 0.61; percentage 
agreement 80.0%) for Berlin criteria and kappa 0.46 
 o
n







pen: first published as 10.1136/rm
dopen-2018-000825 on 5 Decem
ber 2018. Downloaded from
 
13Poddubnyy D, et al. RMD Open 2018;4:e000825. doi:10.1136/rmdopen-2018-000825
Spondyloarthritis
Figure 1 Flow chart of patients with chronic back pain included in diagnostic accuracy of inflammatory back pain study. IBP, 
inflammatory back pain; SpA, spondyloarthritis.
Table 1 Clinical, laboratory and imaging characteristics of patients with chronic back pain who had judgement on IBP and 











Age, years (mean±SD) 36.1±10.2 32.8±9.3 42.7±11.3 39.0±11.4
Male sex, n (%) 60 (68.2) 54 (58.7) 79 (35.4) 193 (47.9)
HLA-B27 positive, n (%) 79 (89.8) 70 (76.1) 83 (37.2) 232 (57.6)
Back pain duration, years (mean±SD) 9.0±7.8 5.3±6.9 12.5±10.9 10.1±9.9
Peripheral oligoarthritis, n (%) 12 (13.6) 20 (21.7) 32 (14.3) 64 (15.9)
Enthesitis, n (%) 21 (23.9) 16 (17.4) 33 (14.8) 71 (17.6)
Dactylitis, n (%) 2 (2.3) 5 (5.4) 10 (4.5) 17 (4.2)
Uveitis, n (%) 13 (14.8) 18 (19.6) 11 (4.9) 42 (10.4)
History of IBD, n (%) 2 (2.3) 4 (4.4) 0 (0) 6 (1.5)
Psoriasis, n (%) 2 (2.3) 13 (14.1) 16 (7.2) 31 (7.7)
SpA family history, n (%) 17 (19.3) 24 (26.1) 45 (20.1) 86 (21.3)
CRP, mg/L (mean±SD) 11.0±16.4 7.1±9.2 2.9±4.3 5.7±9.9
ESR, mm/hour (mean±SD) 22.7±20.8 15.2±13.3 12.0±10.3 15.2±14.6
Radiographic sacroiliitis according to the mNY criteria, n/N (%) 78/85 (91.8) 0/85 0/208 85/378 (22.5)
Active inflammatory changes in the SIJ on MRI, n/N (%) 37/48 (77.1) 51/70 (72.9) 2/77 (2.6) 90/195 (46.2)
Chronic inflammatory changes in the SIJ on MRI, n/N (%) 32/48 (66.7) 38/70 (54.3) 0/77 (0) 70/195 (35.9)
Active inflammatory changes in the spine on MRI, n/N (%) 15/36 (41.7) 13/35 (37.1) 5/84 (6.0) 33/155 (21.3)
Chronic inflammatory changes in the spine on MRI, n/N (%) 11/36 (30.6) 3/35 (8.6) 3/84 (3.6) 17/15 (11.0)
AS, ankylosing spondylitis; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HLA, human leucocyte antigen; IBD, inflammatory 
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Table 2 The prevalence of IBP (%) according to different criteria in patients referred because of chronic back pain












Global evaluation 80.7 81.5 56.1 67.3
Calin’s criteria 79.6 79.4 74.9 76.9
Berlin Criteria 81.8 80.4 67.7 73.7
ASAS criteria 75.0 73.9 60.5 66.8
Diagnosing 
rheumatologist
Global evaluation 92.1 88.0 41.3 63.0
Calin’s criteria 87.5 82.6 73.1 78.4
Berlin criteria 85.2 82.6 55.2 68.0
ASAS criteria 89.8 78.3 64.6 73.2
Patient Calin’s criteria 73.6 76.7 79.5 77.5
Berlin criteria 87.4 85.6 81.7 83.8
ASAS criteria 79.3 68.9 69.0 71.2
AS, ankylosing spondylitis; ASAS, Assessment of SpondyloArthritis international Society; IBP, inflammatory back pain; SpA, 
spondyloarthritis; nr-axSpA, non-radiographic axial spondyloarthritis.
























































































































































ASAS, Assessment of SpondyloArthritis international Society; IBP, inflammatory back pain; LR, likelihood ratio; NPV, negative predictive value; PPV, 
positive predictive value; SpA, spondyloarthritis; axSpA, axial spondyloarthritis.
(95% CI 0.37, 0.56; percentage agreement 77.3%) for 
the ASAS criteria.
diagnostic accuracy of IBP
For diagnostic accuracy analyses of IBP, data from AS 
and nr-axSpA were pooled (table 3). IBP by R-blind had 
a sensitivity of 74%–81% and a specificity of 25%–44% 
for the diagnosis of axSpA, depending on the IBP 
definition applied. Interestingly, global judgement on 
IBP by R-blind numerically exceeded the three sets of 
defined IBP criteria in terms of sensitivity and speci-
ficity; yet, the resulting positive LRs overall were low, 
ranging from 1.1 (Calin criteria) to 1.4 (global judge-
ment of IBP) (table 3). The results were similar when 
we stratified for single study sites or for type of centre: 
for example, the LR+ for IBP according to ASAS criteria 
by R-blind was 1.3 (hospital based) and 1.1 (private 
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Table 4 Sensitivity and specificity of single IBP parameters as assessed by the diagnosing rheumatologist, the blinded 
rheumatologist and patient for the diagnosis of axSpA
IBP parameter



































































































IBP, inflammatory back pain; LR, likelihood ratio; SpA, spondyloarthritis; axSpA, axial spondyloarthritis.
practices), respectively. Overall, the LR+ as a measure 
of diagnostic utility of the symptom of IBP for the diag-
nosis of axSpA was small and substantially smaller than 
expected from published data (LR+ 3–4) due to low 
specificity, independently of the definition of IBP being 
applied.
The ASAS defined IBP criteria had the lowest sensi-
tivity (74.4%), while the Berlin criteria and global judge-
ment of IBP had the highest sensitivity (both 81.1%). 
The specificity of IBP according to R-blind varied from 
24.9% (Calin criteria) to 43.9% (global judgement) 
(table 3). There were no striking differences between 
the three sets of IBP criteria with regard to PPV and 
NPV: the Calin criteria performed slightly less well than 
the Berlin and ASAS criteria.
In the original publication of the Berlin criteria, it 
was speculated that the presence of ≥3 out of 4 items 
(instead of ≥2 out of 4) would yield a high diagnostic 
gain (estimated LR+ 12.4; specificity 97.3%, sensitivity 
33.6%).2 In the settings of DIVERS, however, the sensi-
tivity and specificity of ≥3 out of 4 items of the Berlin 
criteria were 59.8% and 59.9%, respectively, and 
resulted in a small increase of the LR+ from 1.2 to 1.5 
only.
single IBP features
Analysing single IBP parameters, the highest sensitivity 
for the diagnosis of axSpA was observed for ‘improve-
ment of back pain with exercise’ (88.9%), which, 
however, had a low specificity (22.7%) (table 4). ‘Alter-
nating buttock pain’ had the lowest sensitivity (60.0%) 
but the highest specificity (58.2%), and the highest 
LR+ of 1.4 for a single IBP feature according to R-blind.
Blinded as compared to unblinded assessment of IBP
It can be assumed that the judgement on a diagnostic 
test like IBP, which is subject to interpretation, will be 
influenced by knowledge of other diagnostic test results 
(‘diagnostic bias’). Indeed, both sensitivity 90.0% 
versus 81.1% and specificity 58.2% versus 44.0% of IBP 
according to global judgement were higher for R-care 
(unblinded) than for R-blind (table 3). This indeed 
demonstrates a moderate diagnostic bias of R-care 
in the assessment of IBP by knowledge of other SpA 
features. In contrast, the comparison between R-blind 
and R-care according to formal sets of IBP criteria 
(Calin, Berlin, ASAS) revealed no consistent differ-
ences in specificity but lower sensitivities for all three 
sets of criteria when assessed by R-blind (table 3). This 
suggests that ‘global judgement’ on IBP is more suscep-
tible to diagnostic bias than defined sets of IBP criteria.
IBP self-assessment by the patient
With regard to fulfilment of defined sets of IBP criteria, 
little differences were found in the self-assessed preva-
lence of IBP between patients with axSpA and patients 
without axSpA (table 2): the specificities of defined IBP 
criteria, and of single IBP features, were even lower if 
self-assessed by the patient, while the sensitivities were 
comparable to those as assessed by R-blind (tables 3 
and 4), resulting in even slightly lower LR+ of between 
0.9 and 1.1 overall.
diagnostic gain of IBP for the diagnosis of axspA
In DIVERS, axSpA was diagnosed in 44.6% (pretest 
probability of axSpA). According to global judge-
ment on IBP by R-blind, the presence of IBP (LR+ 
1.4) resulted in a post-test probability of axSpA of 
53%. Thus, a moderate diagnostic gain of IBP of 8.4% 
remained despite the low LR+. For comparison, the 
presence of IBP according to R-care—unblinded to 
other patient findings including human leucocyte 
antigen (HLA)-B27 and imaging, and therefore some-
what biassed—had resulted in an increase of axSpA by 
as much as 19.5% (from 44.6% to 63.9%).
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dIsCussIOn
DIVERS is the first real-life diagnostic accuracy study 
on IBP as a diagnostic test for axSpA in the rheuma-
tology setting, that is, in secondary and tertiary care. 
We found a net diagnostic gain of only 2.5%–8.4%, 
if IBP is present, for the likelihood of a diagnosis of 
axSpA. Thus, one important finding at first glance 
is that IBP in the rheumatology setting contributes 
little to establishing the diagnosis of axSpA. On the 
other hand, the majority of referred patients had IBP, 
suggesting an effective selection in primary care of 
patients presenting with chronic back pain for referral 
to rheumatology. Moreover, our study shows that in the 
rheumatology setting, none of the defined sets of IBP 
criteria (Calin, Berlin, ASAS) clearly outperformed 
another one; yet, a tendency for the Calin criteria being 
the least specific set was found.
The sensitivity of IBP according to various defined IBP 
criteria (74.4%–81.1%) or to global judgement on IBP 
(81.1%) among patients with axSpA in DIVERS was very 
similar to published figures of 70.1%–95% in patients 
with AS/axSpA.1–3 However, we found substantially lower 
specificities for all defined sets of IBP criteria, ranging 
from 25.2% to 39.5%, as compared with the original 
publications on IBP (72.5%–81.3%).1–3 As a result, the 
calculated LR+ were low (1.1–1.2) as compared with 
published LR+ for these IBP definitions of 2.9–3.9.1–3 
A plausible explanation for the differences in the spec-
ificities of IBP criteria could be the fact that in two of 
the three earlier studies,1 2 well-selected patients with 
either a clear diagnosis of axSpA or of mechanical back 
pain (no-axSpA) were included (convenience sample), 
whereas in our study undiagnosed and newly referred 
patients were included, thereby reflecting better daily 
rheumatology practice. Since the prevalence of IBP was 
high among referred patients, one must assume that 
IBP has operated as a selection parameter in primary 
care that had triggered referral to the rheumatologist. 
This unmeasured channelling process led to a popula-
tion of referred patients with chronic back pain who 
were enriched for the presence of IBP. In fact, it has 
been proposed in 2005, and has subsequently proven 
effective, to select in primary care for referral to rheu-
matology chronic back patients with age at onset ≤45 
years and at least one additional SpA feature such as 
IBP or a positive HLA-B27 test, both of which increase 
the likelihood of having axSpA.13 In epidemiological 
studies on unselected back pain, prevalence figures for 
IBP of 5%–15% for acute and of 28%–35% for chronic 
back pain have been reported.17 18 The high prevalence 
of IBP of 67.3% in our study indeed supports the notion 
that IBP had been used by primary care physicians to 
select patients for referral, although this was not specif-
ically intended.
The selection of patients with certain SpA features 
for referral is also illustrated in our study by the high 
prevalence of other SpA features including HLA-B27 
(57.6%), a positive family history for SpA (21.3%) or 
uveitis (10.4%); all of them leading to enrichment of 
patients with a higher likelihood of having axSpA. In 
fact, the selected referral of patients with back pain more 
likely to have axSpA is eventually reflected by the high 
rate of a final diagnosis of axSpA (44.6%) in DIVERS 
which is much higher than reported prevalences of 
axSpA of around 5%–12% in unselected patients with 
chronic back pain.19 20 Interestingly, studies with a study 
design similar to DIVERS also revealed high prevalence 
rates of axSpA among referred patients: in the inter-
national ASAS classification criteria for axSpA study, 
the prevalence of axSpA was 66%,5 and in the SPondy-
loArthritis Caught Early cohort, axSpA was diagnosed 
in 41%.21 Although no structured referral protocol was 
recommended in either of these studies, an unmea-
sured preselection process had undoubtfully taken 
place in both,22 suggesting ‘unmeasured’ selection of 
patients for referral likely occurring in other countries 
and settings as well.
The low LR+ of 1.1–1.2 for defined sets of IBP criteria 
suggests at first glance a minor, if any, diagnostic utility 
of IBP in the rheumatology setting. It seems that the 
diagnostic utility of IBP has been already ‘used up’ at 
the time when the patient is referred to the rheuma-
tologist. Yet, a small diagnostic gain is indeed retained, 
partially because the pretest probability (prevalence 
of axSpA) was substantially higher in the rheuma-
tology setting than in primary care: the presence of 
IBP according to global judgement by the blinded 
assessor (LR+ 1.4) resulted in an increase of the prob-
ability of axSpA from 44.6% to 53%, implicating a net 
diagnostic gain of 8.4%, whereas the increase with 
fulfilment of Calin criteria (2.4%), Berlin (4.5%) and 
ASAS criteria (4.5%) was lower than the estimated net 
diagnostic gain of 9%–11% for IBP among unselected 
patients with chronic back pain in primary care (prob-
ability of axSpA increases in primary care from 5% to 
14%–16%).6 19 23
In DIVERS, we also analysed single IBP features, 
among which ‘alternating buttock pain’ had the highest 
specificity and the highest LR+ of 1.4, followed by ‘no 
improvement with rest’ (LR+ 1.3), suggesting that these 
items may provide some diagnostic information in the 
rheumatology setting. We also addressed the self-assess-
ment of IBP by the patient. The resulting sensitivities 
were comparable to those by the blinded rheumatol-
ogist. However, the specificities were similar or even 
lower. The specificity of self-assessment of IBP symp-
toms in unselected patients in primary care is expected 
to be higher but cannot be properly addressed in our 
study.7 13 24
The knowledge of SpA features other than IBP that 
drive towards or away from a diagnosis of axSpA is 
likely to influence the global judgement on the pres-
ence or absence of IBP. Indeed, this potential bias is 
illustrated by both a higher sensitivity and higher spec-
ificity (with a resulting higher LR+ of 2.2 vs 1.4) for the 
diagnosing (unblinded) as compared with the blinded 
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rheumatologist in DIVERS and underscores the neces-
sity in diagnostic accuracy studies for a diagnostic 
test like IBP, which is subject to interpretation, to be 
assessed in a blinded fashion.14 15
The strengths of our study are the high standards 
for the conduct and reporting of diagnostic studies 
including the prospective study design, the inde-
pendent assessment of the diagnostic test of interest 
(IBP) without knowledge of other test results,14 15 the 
multicentre study design with secondary care (four 
private practices) as well as tertiary care centres (one 
university hospital and one large community hospital 
specialised in rheumatology) and the large number of 
consecutive patients. A potential weakness of our study 
conducted in routine rheumatology care is the fact that 
not all patients diagnosed as no-axSpA underwent MRI. 
However, only 22 of patients without MRI (9.8% of all 
patients without SpA patients) had a clinical context 
(IBP plus positive HLA-B27) strongly suggesting axSpA: 
if all of these patients had shown sacroiliitis on MRI and 
had been diagnosed axSpA, a scenario that is unlikely, 
the specificity of IBP (global judgement) had increased 
from 43.9% to 48.8% and the LR+from 1.4 to 1.56.
Of interest, our study strikingly shows how test char-
acteristics and the resulting LR+ vary, depending on the 
setting (primary vs secondary/tertiary care) where these 
tests are applied and depending on whether parame-
ters have operated already as selection parameters for 
referral. The understanding of these potential shifts 
in specificity and LR+ of diagnostic tests is of general 
importance when interpreting data from any study on 
diagnostic test characteristics in medicine. The results 
of this study also confirm that a diagnosis of axSpA 
cannot be made by the presence or absence of single 
parameters (in this case of IBP) but only by assessment 
of all available clinical, laboratory and imaging parame-
ters, interpreted by an experienced physician and after 
careful exclusion of other diagnoses.23
In summary, rheumatologists must be aware that 
their global judgement on IBP might be influenced by 
knowledge of other SpA parameters. Rheumatologists 
must also be aware that many patients referred to them 
for a diagnostic workup of axSpA will have IBP because 
IBP effectively operates in primary care as a selection 
criterion for referral. Although the specificity of IBP 
(and the resulting LR+) is low in the rheumatology 
setting, a small diagnostic gain remains.
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